Ocata Therapeutics Company Profile (NASDAQ:OCAT)

About Ocata Therapeutics

Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCAT
  • CUSIP:
Key Metrics:
  • Previous Close: $8.47
  • 50 Day Moving Average: $8.42
  • 200 Day Moving Average: $6.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.29
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Ocata Therapeutics:

Analyst Ratings

Consensus Ratings for Ocata Therapeutics (NASDAQ:OCAT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2016Cantor FitzgeraldReiterated RatingHold$8.50View Rating Details
11/10/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformView Rating Details
7/10/2015Cowen and CompanyInitiated CoverageOutperformView Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Ocata Therapeutics (NASDAQ:OCAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015Q315($0.09)ViewN/AView Earnings Details
8/6/2015Q215($0.19)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS

Dividends

Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocata Therapeutics (NASDAQ:OCAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2015Robert LanzainsiderSell35,000$8.31$290,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
DateHeadline
News IconOcata Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OCAT)
www.bioportfolio.com - February 18 at 11:50 AM
News IconCompanies Flocking to Japan for Biotech Deals - InvestorIdeas.com (press release) (NASDAQ:OCAT)
www.investorideas.com - February 3 at 12:54 AM
News IconWill The Needle Move For Ocata Therapeutics, Inc. (NASDAQ:OCAT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:OCAT)
wsbeacon.com - January 18 at 12:21 AM
News IconBiotechs are paying a price for their high drug costs (NASDAQ:OCAT)
www.bostonglobe.com - January 8 at 6:41 PM
News IconGlobal Stem Cell Therapy Industry in-Depth Investigation and Analysis Report 2016; New Report Launched (NASDAQ:OCAT)
www.digitaljournal.com - December 27 at 6:50 PM
bloomberg.com logoPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster ... - Bloomberg (NASDAQ:OCAT)
www.bloomberg.com - December 1 at 12:08 AM
bloomberg.com logoPharma CEO Hunts New Trophy After Prostate Cancer Blockbuster (NASDAQ:OCAT)
www.bloomberg.com - November 30 at 11:50 AM
News IconRegenerative medicine market to reach $30,237 million, globally, by ... - WhaTech (NASDAQ:OCAT)
www.whatech.com - November 25 at 6:33 PM
News IconOcata Therapeutics, Inc. OCAT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OCAT)
www.bioportfolio.com - November 18 at 9:48 AM
News IconBioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Yahoo Sports (NASDAQ:OCAT)
sports.yahoo.com - November 12 at 9:10 AM
businesswire.com logoBioTime Co-CEO Dr. Michael D. West to Chair Cell Therapy Track at World Precision Medicine Congress USA 2016 - Business Wire (press release) (NASDAQ:OCAT)
www.businesswire.com - November 10 at 6:24 PM
openpr.com logoRegenerative Medicine Market to Reach $30,237 Million, Globally, by 2022 (NASDAQ:OCAT)
www.openpr.com - October 20 at 12:23 PM
News IconRegenerative Medicine Market to Reach $30,237 Million, Globally by 2022 (NASDAQ:OCAT)
www.pr.com - October 16 at 10:54 AM
News IconEaston resident receives Hartford Anchor Award - Wicked Local Easton (NASDAQ:OCAT)
easton.wickedlocal.com - October 1 at 11:51 AM
News IconWindsor Resident Joe Cymerys Given Anchor Award from his Alma Mater (NASDAQ:OCAT)
patch.com - September 29 at 11:42 AM
News IconGlobal Regenerative Medicine Market Is Expected to Reach $30237 Million by 2022; Finds New Report - Digital Journal (NASDAQ:OCAT)
www.digitaljournal.com - September 22 at 6:12 PM
News IconCantor Fitzgerald Begins Coverage on Ocata Therapeutics (OCAT) - Petro Global News 24 (NASDAQ:OCAT)
petroglobalnews24.com - September 22 at 11:23 AM
News IconOcata Therapeutics Now Covered by Raymond James (OCAT) - Petro Global News 24 (NASDAQ:OCAT)
petroglobalnews24.com - September 21 at 6:11 PM
thestreet.com logoApplied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen - TheStreet.com (NASDAQ:OCAT)
www.thestreet.com - September 20 at 11:49 AM
News IconGlobal Regenerative Medicine Market 2016: is expected reach $30237 million by 2022 - Medgadget (blog) (NASDAQ:OCAT)
www.medgadget.com - September 18 at 10:48 AM
News IconGlobal Regenerative Medicine Market 2016: is expected reach $30,237 million by 2022 (NASDAQ:OCAT)
www.medgadget.com - September 17 at 6:04 PM
News IconRegenerative Medicine Market Trends and Industry Forecast 2016 - 2022 - Medgadget (blog) (NASDAQ:OCAT)
www.medgadget.com - September 16 at 10:03 AM
News IconRegenerative Medicine Market is Expected to Grow CAGR of 33.1% During 2016-2022 (NASDAQ:OCAT)
empowerednews.net - September 14 at 10:50 AM
bizjournals.com logoChinese biotech Vcanbio opens first U.S. subsidiaries in Natick - Boston Business Journal (blog) (NASDAQ:OCAT)
www.bizjournals.com - September 13 at 11:24 AM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) From The Analysts Point of View - National Daily Press (NASDAQ:OCAT)
www.nationaldailypress.com - September 9 at 11:14 AM
bizjournals.com logoPharma Leader Series: Top Stem Cell Companies Report 2016-2026: Market Analysis and Leading Players in the United States, Europe, Israel and Asia (NASDAQ:OCAT)
www.bizjournals.com - September 6 at 11:18 AM
finance.yahoo.com logoRegenerative Medicine Market to Reach $30237 Million, Globally, by 2022 - Allied Market Research - Yahoo Finance (NASDAQ:OCAT)
finance.yahoo.com - September 1 at 9:43 AM
News IconRegenerative Medicine Market to Reach $30,237 Million, Globally, by 2022 - Allied Market Research (NASDAQ:OCAT)
www.prnewswire.co.uk - August 31 at 11:35 AM
bloomberg.com logoKey Executives for Ocata Therapeutics, Inc. (NASDAQ:OCAT)
www.bloomberg.com - August 23 at 6:47 PM
News IconResearch report explores the global age related macular degeneration market consumption forecast to 2021 covering ... - WhaTech (NASDAQ:OCAT)
www.whatech.com - July 26 at 6:54 PM
marketexclusive.com logoJapan is Breathing Life into the Stem Cell Space, Astellas Pharma NPV (OTCMKTS:ALPMF) & Pluristem Therapeutics ... - Market Exclusive (NASDAQ:OCAT)
marketexclusive.com - July 21 at 6:54 PM
News IconKeryx Biopharmaceuticals Appoints Two New Board Members - PharmiWeb.com (press release) (NASDAQ:OCAT)
www.pharmiweb.com - June 21 at 10:59 AM
News IconCynata Appoints Paul K Wotton Ph.D. to Board of Directors - irasia.com (press release) (NASDAQ:OCAT)
www.irasia.com - June 9 at 9:32 AM
News IconCantor Fitzgerald Initiates a Buy Rating on Glaukos - Markets.co (NASDAQ:OCAT)
www.markets.co - June 3 at 9:28 AM
News IconOcata Therapeutics Inc (OCAT) Profit Expected to Increase - OctaFinance.com (NASDAQ:OCAT)
www.octafinance.com - February 7 at 2:45 PM
stocksdaily.net logoWill Ocata Therapeutics, Inc. (NASDAQ:OCAT) Surprise Analysts This Quarter? - Stocks Daily (NASDAQ:OCAT)
www.stocksdaily.net - January 27 at 2:00 PM
seekingalpha.com logoOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha (NASDAQ:OCAT)
seekingalpha.com - January 26 at 2:31 PM
istreetwire.com logoHot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT), Ocata Therapeutics, Inc. (OCAT), Dyax ... - iStreetWire (NASDAQ:OCAT)
www.istreetwire.com - January 25 at 1:48 PM
News IconAstellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - FierceBiotech (NASDAQ:OCAT)
www.fiercebiotech.com - January 22 at 1:31 PM
News IconSmall investors oppose Ocata sale; $379M offer deemed too low for drug 'worth ... - Worcester Telegram (NASDAQ:OCAT)
www.telegram.com - January 21 at 1:44 PM
capitalcube.com logoOcata Therapeutics, Inc. – Value Analysis (NASDAQ:OCAT) : January 20, 2016 (NASDAQ:OCAT)
www.capitalcube.com - January 20 at 11:25 AM

Social

What is Ocata Therapeutics' stock symbol?

Ocata Therapeutics trades on the NASDAQ under the ticker symbol "OCAT."

How do I buy Ocata Therapeutics stock?

Shares of Ocata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ocata Therapeutics stock cost?

One share of Ocata Therapeutics stock can currently be purchased for approximately $8.47.

Ocata Therapeutics (NASDAQ:OCAT) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Earnings History Chart

Earnings by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Dividend History Chart

Dividend Payments by Quarter for Ocata Therapeutics (NASDAQ:OCAT)

Last Updated on 2/27/2017 by MarketBeat.com Staff